Story perspectives

Moderna Surpasses Revenue Estimates Amid Vaccine Challenges

2/13/2026

Summary

Story summary

Moderna reported fourth-quarter revenue of $678 million in 2023, surpassing Wall Street's estimate of $626.1 million, primarily due to COVID-19 vaccine sales.
The company incurred a loss of $2.11 per share, which was better than the anticipated $2.54 loss.
CEO Stéphane Bancel announced a goal of 10% revenue growth by 2026, with sales expected to be evenly split between U.S. and international markets.
The FDA declined to review Moderna's flu vaccine application, citing trial design flaws, which analysts consider a significant challenge for future vaccine prospects.
Despite these challenges, Moderna's shares increased by 36% year-to-date prior to the earnings report.

1 of 1

Story summary

Moderna reported fourth-quarter revenue of $678 million in 2023, surpassing Wall Street's estimate of $626.1 million, primarily due to COVID-19 vaccine sales.
The company incurred a loss of $2.11 per share, which was better than the anticipated $2.54 loss.
CEO Stéphane Bancel announced a goal of 10% revenue growth by 2026, with sales expected to be evenly split between U.S. and international markets.
The FDA declined to review Moderna's flu vaccine application, citing trial design flaws, which analysts consider a significant challenge for future vaccine prospects.
Despite these challenges, Moderna's shares increased by 36% year-to-date prior to the earnings report.